Loading...
Loading...
DNTH| Name | Value |
|---|---|
| Revenues | 969.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 969.0K |
| Operating Expense | 5,457.0K |
| Operating I/L | -5,457.0K |
| Other Income/Expense | 2,173.0K |
| Interest Income | 687.0K |
| Pretax | -3,284.0K |
| Income Tax Expense | 179.0K |
| Net Income/Loss | -3,284.0K |
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development and delivery of novel monoclonal antibodies for severe autoimmune and inflammatory diseases. Its lead product, DNTH103, is currently in phase 1 clinical trials for conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
